Oct 27, 2022Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
Emerging infectious diseases where no protective vaccines are currently available SuVax™ targets Sudan ebolavirus, origin of a current disease outbreak in Uganda PRINCETON, N.J. , Oct. 27, 2022...
Oct 25, 2022
Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022 PRINCETON, N.J., Oct. 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a...
Oct 20, 2022
Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern Time Soligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, to vote by 11:59 p.m., Eastern Time on...
Sep 23, 2022Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
- Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time - Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59
Sep 8, 2022
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...